Buy_老虎社区_美港股上老虎

Edwardtoh
2021-11-15

Buy

Is It Too Late to Buy Novavax Stock?

The stock has made early investors rich -- but can it do the same for those who buy it today?

Is It Too Late to Buy Novavax Stock?

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":873425008,"tweetId":"873425008","gmtCreate":1636979674255,"gmtModify":1636979674427,"author":{"id":3586301355400538,"authorId":3586301355400538,"authorIdStr":"3586301355400538","name":"Edwardtoh","avatar":"https://static.tigerbbs.com/b46042c9b9b5dcea7d55f33bccb139cc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Buy&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Buy&nbsp;</p></body></html>","text":"Buy","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/873425008","repostId":2183965024,"repostType":4,"repost":{"id":"2183965024","pubTimestamp":1636978272,"share":"https://www.laohu8.com/m/news/2183965024?lang=&edition=full","pubTime":"2021-11-15 20:11","market":"us","language":"en","title":"Is It Too Late to Buy Novavax Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2183965024","media":"Motley Fool","summary":"The stock has made early investors rich -- but can it do the same for those who buy it today?","content":"<p>Early investors in COVID-19 vaccine makers <b>Moderna</b> and <b>Novavax</b> (NASDAQ:NVAX) have earned significant returns over the past couple of years, with both stocks up over 1,000% since the start of 2020 (the <b>S&amp;P 500</b> has only risen by 44% during that time frame). Novavax's 4,000% returns are astronomical even though the company's vaccine hasn't yet gotten the go-ahead from the U.S. Food and Drug Administration (FDA) -- in fact, it hasn't even filed for an Emergency Use Authorization (EUA) yet.</p>\n<p>It's a risky stock to be holding, but the good news is investors can hedge their positions. However, if you don't already have Novavax in your portfolio, is it worth taking a chance on the stock today?</p>\n<h2>Its vaccine has obtained approval -- just not in the U.S., yet</h2>\n<p>On Nov. 1, Novavax announced the first authorization for its COVID-19 vaccine in Indonesia. It also anticipates more approvals coming from other parts of the world in the weeks ahead, including from India and the Philippines. The company has filed for Emergency Use Listing from the World Health Organization, which could lead to even more countries approving its vaccine.</p>\n<p>In the U.S., Novavax plans to submit an application for an EUA with the FDA before the end of this year, but there's no guarantee it will get the go-ahead from the agency. Nearly 60% of the U.S. population is fully vaccinated against COVID, and former FDA commissioner Dr. Scott Gottlieb recently said he believed that the pandemic may be over in the U.S. by January (becoming endemic at that point) -- so there may not be a compelling reason for the agency to approve another vaccine.</p>\n<h2>Would that be enough to justify its valuation?</h2>\n<p>Novavax reported a net loss of $322.4 million for the period ending Sept. 30, with revenue totaling $178.8 million. The company's top line rose 14% year over year due to an increase in royalties, while revenue from grants and government contracts declined. If it gets multiple vaccine approvals, that could go a long way in strengthening Novavax's top line and making it a better investment.</p>\n<p>The company anticipates having the capacity to produce more than 2 billion doses of its vaccine next year. At a projected price of $16 per injection, that could translate into more than $30 billion in revenue for Novavax next year. But that would be under a best-case scenario in which it could sell all of its production at that price.</p>\n<p>Today, Novavax's stock trades at 10 times its revenue, compared to a multiple of 8 for Moderna, but investors are buying it for its potential rather than what it has accomplished thus far. If Novavax is able to obtain widespread approval for its COVID-19 vaccine, there could be a path for it to deliver the revenue growth it needs to be an attractive investment, even at its nearly $13 billion valuation.</p>\n<h2>Should you buy Novavax stock today?</h2>\n<p>There is hope beyond just its COVID vaccine, as Novavax also has an influenza vaccine (Nanoflu) that could generate $550 million in peak annual revenue. But the hype around Novavax is undoubtedly because of its COVID-19 vaccine, and if that underwhelms, it could lead to a significant sell-off of the stock. It certainly doesn't help that there are also multiple companies making pills to battle COVID, so there may be less of an incentive for unvaccinated individuals to opt for a shot.</p>\n<p>It may not be too late to buy Novavax, but that's only under the assumption that it has a big year in 2022 and that countries approve its COVID-19 vaccine. It's dangerous for investors to buy a stock based on a best-case scenario. So unless you have an extremely high risk tolerance, you're probably better off going with other growth stocks instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late to Buy Novavax Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late to Buy Novavax Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 20:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/15/is-it-too-late-to-buy-novavax-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Early investors in COVID-19 vaccine makers Moderna and Novavax (NASDAQ:NVAX) have earned significant returns over the past couple of years, with both stocks up over 1,000% since the start of 2020 (the...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/15/is-it-too-late-to-buy-novavax-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/11/15/is-it-too-late-to-buy-novavax-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183965024","content_text":"Early investors in COVID-19 vaccine makers Moderna and Novavax (NASDAQ:NVAX) have earned significant returns over the past couple of years, with both stocks up over 1,000% since the start of 2020 (the S&P 500 has only risen by 44% during that time frame). Novavax's 4,000% returns are astronomical even though the company's vaccine hasn't yet gotten the go-ahead from the U.S. Food and Drug Administration (FDA) -- in fact, it hasn't even filed for an Emergency Use Authorization (EUA) yet.\nIt's a risky stock to be holding, but the good news is investors can hedge their positions. However, if you don't already have Novavax in your portfolio, is it worth taking a chance on the stock today?\nIts vaccine has obtained approval -- just not in the U.S., yet\nOn Nov. 1, Novavax announced the first authorization for its COVID-19 vaccine in Indonesia. It also anticipates more approvals coming from other parts of the world in the weeks ahead, including from India and the Philippines. The company has filed for Emergency Use Listing from the World Health Organization, which could lead to even more countries approving its vaccine.\nIn the U.S., Novavax plans to submit an application for an EUA with the FDA before the end of this year, but there's no guarantee it will get the go-ahead from the agency. Nearly 60% of the U.S. population is fully vaccinated against COVID, and former FDA commissioner Dr. Scott Gottlieb recently said he believed that the pandemic may be over in the U.S. by January (becoming endemic at that point) -- so there may not be a compelling reason for the agency to approve another vaccine.\nWould that be enough to justify its valuation?\nNovavax reported a net loss of $322.4 million for the period ending Sept. 30, with revenue totaling $178.8 million. The company's top line rose 14% year over year due to an increase in royalties, while revenue from grants and government contracts declined. If it gets multiple vaccine approvals, that could go a long way in strengthening Novavax's top line and making it a better investment.\nThe company anticipates having the capacity to produce more than 2 billion doses of its vaccine next year. At a projected price of $16 per injection, that could translate into more than $30 billion in revenue for Novavax next year. But that would be under a best-case scenario in which it could sell all of its production at that price.\nToday, Novavax's stock trades at 10 times its revenue, compared to a multiple of 8 for Moderna, but investors are buying it for its potential rather than what it has accomplished thus far. If Novavax is able to obtain widespread approval for its COVID-19 vaccine, there could be a path for it to deliver the revenue growth it needs to be an attractive investment, even at its nearly $13 billion valuation.\nShould you buy Novavax stock today?\nThere is hope beyond just its COVID vaccine, as Novavax also has an influenza vaccine (Nanoflu) that could generate $550 million in peak annual revenue. But the hype around Novavax is undoubtedly because of its COVID-19 vaccine, and if that underwhelms, it could lead to a significant sell-off of the stock. It certainly doesn't help that there are also multiple companies making pills to battle COVID, so there may be less of an incentive for unvaccinated individuals to opt for a shot.\nIt may not be too late to buy Novavax, but that's only under the assumption that it has a big year in 2022 and that countries approve its COVID-19 vaccine. It's dangerous for investors to buy a stock based on a best-case scenario. So unless you have an extremely high risk tolerance, you're probably better off going with other growth stocks instead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":598,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}